ABSTRACT
Tobacco smoke, alone or combined with alcohol, is the predominant cause of head and neck cancer (HNC). Here, we further explore how tobacco exposure contributes to cancer development by mutational signature analysis of 265 whole-genome sequenced HNC from eight countries. Six tobacco-associated mutational signatures were detected, including some not previously reported. Differences in HNC incidence between countries corresponded with differences in mutation burdens of tobacco-associated signatures, consistent with the dominant role of tobacco in HNC causation. Differences were found in the burden of tobacco-associated signatures between anatomical subsites, suggesting that tissue-specific factors modulate mutagenesis. We identified an association between tobacco smoking and three additional alcohol-related signatures indicating synergism between the two exposures. Tobacco smoking was associated with differences in the mutational spectra and repertoire of driver mutations in cancer genes, and in patterns of copy number change. Together, the results demonstrate the multiple pathways by which tobacco smoke can influence the evolution of cancer cell clones.
Competing Interest Statement
L.B.A. is a co-founder, CSO, scientific advisory member, and consultant for io9, has equity and receives income. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. L.B.A. is also a compensated member of the scientific advisory board of Inocras. L.B.A.'s spouse is an employee of Biotheranostics. E.N.B. and L.B.A. declare U.S. provisional patent applications filed with UCSD with serial numbers 63/289,601; 63/269,033; and 63/483,237. A.A. and L.B.A. declare U.S. provisional patent application filed with UCSD with serial number 63/366,392. L.B.A. also declares U.S. provisional application 63/412,835 and international application PCT/US2023/010679 filed with UCSD. L.B.A. is also an inventor of a US Patent 10,776,718 for source identification by non-negative matrix factorization. All other authors declare that they have no competing interests.
Funding Statement
This work was delivered as part of the Mutographs team supported by the Cancer Grand Challenges partnership funded by Cancer Research UK (C98/A24032). Work at the Wellcome Sanger Institute was also supported by the Wellcome Trust (grants 206194 and 220540/Z/20/A), and work at the IARC/WHO was supported by regular budget funding. This work was also supported by the US National Institute of Health grants R01ES032547-01, R01CA269919-01, and 1U01CA290479-01 to L.B.A. as well as by L.B.A.'s Packard Fellowship for Science and Engineering. The research performed in L.B.A.'s lab was supported by UC San Diego Sanford Stem Cell Institute. The head and neck cancer collection received funding from the European Union's Horizon 2020 research and innovation program under grant no. 825771 and the Sao Paulo Research Foundation, FAPESP 2018/26297-3. J.P. and F.G. were partially supported by Italian Ministry of Health - Ricerca Corrente. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was submitted and approved by the IARC Ethics Committee. Informed consent was obtained from all participants. Ethical approvals were obtained from each Local Research Ethics Committee and Federal Ethics Committee as listed: Brazilian National Cancer Institute, Rio de Janeiro, Brazil University of Sao Paulo Medical School, Sao Paulo, Brazil Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy Associaçao de Combate ao Cancer em Goias Hospital Araujo Jorge, Goiania, Brazil School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Instituto de Oncologia Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina National Institute of Public Health, Bucharest, Romania Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Saint Mary Clinic of General and Esophageal Surgery, Bucharest, Romania Barretos Cancer Hospital, Barretos, Brazil Hospital Santa Rita de Cassia - Associaçao Feminina de Educaçao e Combate ao Cancer (AFECC), Vitoria, Brazil Pathology Department, Federal University of Espirito Santo, Vitoria, Brazil Charles University in Prague, 2nd Faculty of Medicine, IPHPM, Prague, Czech Republic A.C.Camargo Cancer Center, Sao Paulo, Brazil Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padova, Italy Regional Authority of Public Health, Slovak Republic Hospital Universitario Fundacion Santa Fe de Bogota, Bogota, Colombia
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
Whole genome sequencing data and patient metadata are deposited in the European Genome-phenome Archive (EGA) associated with study EGAS00001005450. Mutational catalogs for the PCAWG dataset can be accessed at https://dcc.icgc.org/releases/PCAWG. All other data is provided in the accompanying Supplementary Tables.